San Diego-based Invivoscribe announced Monday that it’s entered into a long-term collaboration with biotech giant Thermo Fisher Scientific to develop cancer tests.
Under the terms of the agreement, Invivoscribe will manufacture and commercialize in vitro cancer tests on Thermo Fisher’s next-generation sequencing platform, the Ion PGM DX system. The San Diego firm will also develop associated bioinformatics software, the company stated.
“Through our collaboration, we will leverage Thermo Fisher’s cutting-edge, next-generation sequencing (NGS) technology and Invivoscribe’s development expertise in cancer diagnostics and regulatory and quality systems to provide diagnostic tests with superior clinical sensitivity,” said Jeffrey Miller, CEO of Invivoscribe, in a statement. “We are also very excited to provide our optimized NGS tests with comprehensive bioinformatics software, so our customers can perform the entire testing and reporting process…within their laboratories.”
Financial details were not disclosed.
Invivoscribe has similar development deals for companion diagnostics with Novartis and Astellas Pharma Inc. The company will announce additional companion diagnostic deals throughout the year, according to the Invivoscribe news release.
